Skip to main
GILD

Gilead Sciences (GILD) Stock Forecast & Price Target

Gilead Sciences (GILD) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 47%
Buy 40%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Gilead Sciences is well-positioned in the market with strong and successful products in the areas of HIV, hepatitis, and oncology. The company's pipeline, particularly in the areas of CAR-T cell therapy and oncology, has the potential to bring in significant revenue in the future. However, there are risks to consider, including competition, pricing pressures, and potential legal issues with patents. Despite these risks, the company's commitment to sustainability and transparency, strong partnerships and acquisitions, and diverse product portfolio make it a strong investment opportunity.

Bears say

Gilead Sciences is poised for long-term growth potential thanks to its strong presence in the HIV and hepatitis treatment markets and its promising oncology pipeline. However, the recent acquisition of Trodelvy comes with risks and the company's questionable track record in oncology M&A may cause investors to approach with caution. With strong cash flows from their existing franchises and potential catalysts in the short term, the outlook for Gilead Sciences is mixed, but promising.

Gilead Sciences (GILD) has been analyzed by 15 analysts, with a consensus rating of Buy. 47% of analysts recommend a Strong Buy, 40% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Gilead Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Gilead Sciences (GILD) Forecast

Analysts have given Gilead Sciences (GILD) a Buy based on their latest research and market trends.

According to 15 analysts, Gilead Sciences (GILD) has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $156.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $156.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Gilead Sciences (GILD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.